ArticleScandinavian journal of trauma, resuscitation and emergency medicine2026
Gelatin 4% and hydroxyethyl starch (130/0.42) impair clot formation in a human ex vivo whole-blood resuscitation model.
Article in Scandinavian journal of trauma, resuscitation and emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColloid solutions provide effective intravascular volume expansion but can impair hemostasis, which is particularly critical after trauma-associated hemorrhagic shock. The differential effects of specific colloids on plasmatic coagulation, platelet function and complement activation, especially when used alongside crystalloids, are still underexplored. We therefore examined graded hemodilution with gelatin or hydroxyethyl starch, alone and in combination with a balanced crystalloid, in an ex vivo human whole-blood model over time.
methodsWe used a citrate- and heparin-free human ex vivo whole-blood model to assess the effects of volume dilution with a balanced crystalloid (Jonosteril), gelatin solution (Gelafundin 4%) and hydroxyethyl starch (HES 130/0.42, 6%; Tetraspan). Whole-blood was diluted at increasing ratios up to 4:6 (diluent:blood), incubated for 30 minutes at 37 °C and analyzed for blood gases, standard coagulation tests, platelet activation (CD62P), von Willebrand factor (vWF), thrombin-antithrombin complexes, complement activation and viscoelastic parameters by ROTEM (EXTEM, INTEM, FIBTEM).
resultsAt high dilution ratios, colloid-diluted samples exhibited more frequent macroscopic clotting and significantly lower pH with more pronounced base deficit than Jonosteril. Gelafundin, but not Jonosteril or Tetraspan, increased vWF levels over time, while CD62P expression, thrombin-antithrombin complexes and complement markers remained unchanged. ROTEM revealed a clearly hypocoagulable profile after dilution with Gelafundin or Tetraspan, most pronounced with HES, with prolonged clotting time and clot formation time, reduced a-angle and maximum clot firmness. When combining Jonosteril with increasing colloid fractions at fixed dilution, these changes followed a non-linear, ratio-dependent pattern.
conclusionBalanced colloids, particularly HES 130/0.42, exert intrinsic, ratio-dependent adverse effects on clot formation beyond simple dilution, suggesting that hemostatic safety may depend not only on fluid type but also on the tolerated proportion of colloid within resuscitation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.